Covaxin 77.8% effective against Covid-19 in Lancet study
Skip to main content
  • Home
  • Economy
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Features
  • Epaper
  • More
    • Subscribe
    • COVID-19
    • Bangladesh
    • Splash
    • Videos
    • Games
    • Long Read
    • Infograph
    • Interviews
    • Offbeat
    • Thoughts
    • Podcast
    • Quiz
    • Tech
    • Archive
    • Trial By Trivia
    • Magazine
    • Supplement
  • বাংলা
The Business Standard

Monday
August 08, 2022

Sign In
Subscribe
  • Home
  • Economy
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Features
  • Epaper
  • More
    • Subscribe
    • COVID-19
    • Bangladesh
    • Splash
    • Videos
    • Games
    • Long Read
    • Infograph
    • Interviews
    • Offbeat
    • Thoughts
    • Podcast
    • Quiz
    • Tech
    • Archive
    • Trial By Trivia
    • Magazine
    • Supplement
  • বাংলা
MONDAY, AUGUST 08, 2022
Covaxin 77.8% effective against Covid-19 in Lancet study

Coronavirus chronicle

Hindustan Times
12 November, 2021, 09:25 am
Last modified: 12 November, 2021, 09:30 am

Related News

  • Indian drug regulator okays Covaxin for 6-12 year olds, Corbevax for 5-12 bracket
  • Bharat Biotech on WHO's Covaxin supply suspension: No impact on efficacy, safety
  • WHO suspends Covaxin supplies under UN procurement
  • India gives conditional market nod for Covishield and Covaxin
  • India's Bharat Biotech says Covaxin booster shot neutralises Omicron

Covaxin 77.8% effective against Covid-19 in Lancet study

According to the study, efficacy data of the whole virion-inactivated vaccine further demonstrates 63.6% protection against asymptomatic disease and 65.2% protection against the B.1.617.2 Delta variant

Hindustan Times
12 November, 2021, 09:25 am
Last modified: 12 November, 2021, 09:30 am
Covaxin 77.8% effective against Covid-19 in Lancet study

Analysis data on the safety and efficacy of Bharat Biotech's vaccine against Covid-19, Covaxin, following its Phase 3 clinical trials, has been peer-reviewed and published in the medical journal, The Lancet.

It came four months after the India-based company demonstrated, in a published pre-print study, that its vaccine against the coronavirus disease had 77.8% efficacy against symptomatic cases and 93.4% against severe symptomatic cases.

According to the study, efficacy data of the whole virion-inactivated vaccine further demonstrates 63.6% protection against asymptomatic disease and 65.2% protection against the B.1.617.2 Delta variant.

"The Lancet peer review confirms the efficacy analysis that demonstrates Covaxin to be effective against Covid-19. Covaxin is the only Covid-19 vaccine to have demonstrated efficacy data from Phase 3 clinical trials against the Delta variant at 65.2%," said Bharat Biotech in a statement after The Lancet published the study on Friday.

The efficacy analysis was done after the evaluation of 130 confirmed Covid-19 cases, with 24 observed in the vaccine group as against 106 in the placebo group.

Bharat Biotech developed the anti-Covid jab in partnership with the Indian Council of Medical Research (ICMR) and the National Institute of Virology in Pune.

The company had received strains of Sars-CoV-2 isolated by the Indian government's apex virology laboratory in March 2020.

"The peer review of Covaxin's Phase 3 clinical trial data in The Lancet, an authoritative voice in global medicine, validates our commitment to data transparency and meeting the stringent peer review standards of world-leading medical journals," Krishna Ella, chairman and managing director of Bharat Biotech, said in a statement.

"The data from our product development and clinical trials has been published in 10 peer-reviewed journals, making Covaxin one of the most highly published Covid-19 vaccines in the world. This accomplishment reflects the undeterred commitment by my team members at Bharat Biotech, our public partners, the ICMR, the National Institute of Virology and the trust imposed by our trial participants who made this happen," Ella said.

The Phase 3 trial efficacy and safety study involved 25,800 volunteers across 25 sites in India. According to the company, Covaxin was well tolerated and the Data Safety Monitoring Board didn't report any safety concerns related to the vaccine.

"The safety profile of Covaxin is now well established based on inactivated vaccines technology, and in large part due to the extensive 25-year safety track record of Bharat Biotech's vero cell manufacturing platform," the company said in its statement.

On November 3, the vaccine was granted emergency-use listing by the World Health Organization (WHO), giving various countries to expedite their own regulatory nods to import Covaxin vials.

Balram Bhargava, director general of the ICMR, said, "Following successful isolation of the Sars-CoV-2 virus at the ICMR-National Institute of Virology in Pune, the ICMR and Bharat Biotech embarked upon one of the most successful public-private partnerships to develop the virus isolate into an effective Covid-19 vaccine.

"I am delighted to see that the Phase 3 efficacy data has also been published in The Lancet, one of the most reputed journals worldwide. It speaks highly about the strong position of Covaxin among other global front-runners [with respect to] Covid-19 vaccines. The bench-to-bedside journey of Covaxin in less than 10 months showcases the immense strength of Atmanirbhar Bharat along with the Indian academia and industry in fighting against the odds and carving a niche in the global community."

According to the company, its emergency-use authorisation application is in process in at least 50 countries.

"With more than 150 million doses manufactured and supplied, and with an excellent safety and efficacy profile, Covaxin is a major contributor to the global fight against the Covid-19 pandemic. Covaxin is currently being evaluated in controlled clinical trials among children aged 2-18, with results available during Q4 this year. Bharat Biotech is poised to achieve its goal of an annualised capacity of 1 billion doses of Covaxin by the end of 2021," the company said in its statement.

Top News

COVAXIN

Comments

While most comments will be posted if they are on-topic and not abusive, moderation decisions are subjective. Published comments are readers’ own views and The Business Standard does not endorse any of the readers’ comments.

Top Stories

  • Denim industry banks on new tech for further leap
    Denim industry banks on new tech for further leap
  • TBS file photo
    Now 99% Bangladesh products come under China’s duty-free offer
  • Picture: Collected
    The six billion dollar man

MOST VIEWED

  • People line up for nucleic acid tests during lockdown, amid the coronavirus disease (COVID-19) pandemic, in Shanghai, China, May 26, 2022. REUTERS/Aly Song
    China's Sanya holiday hotspot shuts duty-free malls, venues to curb Covid
  • FILE PHOTO: People wearing protective face masks walk amid concerns over the new coronavirus disease (COVID-19) in Pyongyang, North Korea May 15, 2020, in this photo released by Kyodo. Mandatory credit Kyodo/via REUTERS
    North Korea marks end of first Covid wave, but risks persist
  • A woman holds a small bottle labelled with a "Coronavirus COVID-19 Vaccine" sticker and a medical syringe in this illustration taken October 30, 2020. REUTERS/Dado Ruvic/File Photo
    South Africa reports first death causally linked to Covid vaccine
  • 'Living with Covid': Where the pandemic could go next
    'Living with Covid': Where the pandemic could go next
  • A worker, wearing a protective suit following the coronavirus disease (COVID-19) outbreak, transports luggage on the tarmac of Wuhan Tianhe International Airport, on a hot summer day in Wuhan, Hubei province, China July 14, 2022. cnsphoto via REUTERS
    China's Wuhan locks down 1m residents amid new Covid cases
  • Covid: CDC flags Bangladesh and 5 other countries as ‘high risk’ for travel
    Covid: CDC flags Bangladesh and 5 other countries as ‘high risk’ for travel

Related News

  • Indian drug regulator okays Covaxin for 6-12 year olds, Corbevax for 5-12 bracket
  • Bharat Biotech on WHO's Covaxin supply suspension: No impact on efficacy, safety
  • WHO suspends Covaxin supplies under UN procurement
  • India gives conditional market nod for Covishield and Covaxin
  • India's Bharat Biotech says Covaxin booster shot neutralises Omicron

Features

Deeply depressed and afraid of living in total darkness, the Noakhali-based housewife Rasheda desires nothing but to get her vision back. Photo: Noor-A-Alam

Blind people need 25,000 corneas. Sandhani gets around 25

7m | Panorama
Picture: Collected

The six billion dollar man

1h | Panorama
Safa Shareef’s bridal make-up: Contemporary with a ‘deshi’ touch

Safa Shareef’s bridal make-up: Contemporary with a ‘deshi’ touch

23h | Mode
Infograph: TBS

Why a drastic fuel price hike is dangerous

1d | Panorama

More Videos from TBS

How Google Maps operates in Bangladesh

How Google Maps operates in Bangladesh

12h | Videos
Is BPC really in loss?

Is BPC really in loss?

14h | Videos
Reasons behind Putin-Erdogan's meeting in Sochi

Reasons behind Putin-Erdogan's meeting in Sochi

18h | Videos
Dr Jamaluddin Ahmed talks about recent fuel price hike

Dr Jamaluddin Ahmed talks about recent fuel price hike

18h | Videos

Most Read

1
Diesel price hiked by Tk34 per litre, Octane by Tk46
Energy

Diesel price hiked by Tk34 per litre, Octane by Tk46

2
Housing projects sprouting up by Dhaka-Mawa expressway
Real Estate

Housing projects sprouting up by Dhaka-Mawa expressway

3
July remittance hits two-year high
Economy

July remittance hits two-year high

4
Infographic: TBS
Banking

Dollar rate will be left to market after two months: Governor

5
Bangladesh to resume talks for Ukrainian wheat import
Economy

Bangladesh to resume talks for Ukrainian wheat import

6
A liquefied natural gas (LNG) tanker is tugged towards a thermal power station in Futtsu, east of Tokyo, Japan November 13, 2017. REUTERS/Issei Kato/File Photo
Energy

Summit proposes long-term LNG supply to Petrobangla

EMAIL US
contact@tbsnews.net
FOLLOW US
WHATSAPP
+880 1847416158
The Business Standard
  • About Us
  • Contact us
  • Sitemap
  • Privacy Policy
  • Comment Policy
Copyright © 2022
The Business Standard All rights reserved
Technical Partner: RSI Lab

Contact Us

The Business Standard

Main Office -4/A, Eskaton Garden, Dhaka- 1000

Phone: +8801847 416158 - 59

Send Opinion articles to - oped.tbs@gmail.com

For advertisement- sales@tbsnews.net